Printer Friendly

Consumers Ultimate Winners in Generic Drug Victory: Ranbaxy Prevails in Cefuroxime Axetil Challenge.

Business Editors/Legal Writers/Health/Medical Writers


IRVINE, Calif.--(BUSINESS WIRE)--April 21, 2004

Powerhouse IP Law Firm Knobbe, Martens, Olson & Bear, LLP

Instrumental in Denying GlaxoSmithKline Damages; Latest in a

Recent Trend of Big Wins

Knobbe, Martens, Olson & Bear, LLP, is pleased to announce that its client, Ranbaxy Laboratories Limited and Ranbaxy Pharmaceuticals, Inc. ("Ranbaxy") has prevailed in the patent infringement lawsuit brought by GlaxoSmithKline ("GSK") relating to Ranbaxy's generic version of GSK's antibiotic "Ceftin(R)." While GSK had sought damages, Ranbaxy's victory means the company will not be ordered to pay any money to GSK.

GSK brought the matter before the U.S. District Court for the District of New Jersey in October of 2000. The district court originally granted GSK a preliminary injunction that initially kept Ranbaxy from marketing its antibiotic. However, in 2001, Ranbaxy prevailed on its appeal to the United States Court of Appeals for the Federal Circuit, and launched its product after that Court vacated the preliminary injunction. Now, after a full trial, the district court determined that Ranbaxy's antibiotic does not infringe GSK's patent rights and Ranbaxy is not required to pay any money to GSK.

Darrell L. Olson, lead counsel for Ranbaxy and a litigation partner with Knobbe, Martens, Olson & Bear, stated: "We are delighted with the outcome for Ranbaxy. The dedication of Ranbaxy through this litigation and our dedication to the client were instrumental to achieving this victory. This was truly a team effort."

"Ranbaxy's efforts to bring lower cost generic drugs to consumers often meet patent challenges from other pharmaceutical companies. Our job is to defend Ranbaxy's ability to bring these products to market, and we are pleased that Ranbaxy has ultimately prevailed in bringing its cefuroxime axetil product to market over GSK's patent challenge," said William R. Zimmerman, a litigation partner with Knobbe, Martens, Olson & Bear who works closely with Ranbaxy in its intellectual property matters.

Ranbaxy Laboratories Limited, the parent company of Ranbaxy Pharmaceuticals, Inc., is the ninth largest generic pharmaceutical company in the world, according to Med Ad News, October 2001, and is the largest pharmaceutical company in India. It has been developing generic pharmaceuticals for over 41 years and is a market leader in the pharmaceutical industry. Jay R. Deshmukh, Vice President Intellectual Property Worldwide for Ranbaxy, commented: "This victory is another step forward in the company's generic drug efforts, as well as a step forward in achieving the company's mission of becoming a research-based international pharmaceutical company. The company could not be more pleased with the results in this case."

The trial attorneys from Knobbe, Martens, Olson & Bear who represented Ranbaxy included the following partners: Darrell L. Olson, William R. Zimmerman, Douglas G. Muehlhauser and Karen Vogel Weil, and associates: Brian C. Horne, Payson LeMeilleur, and Thomas P. Krzeminski.

With over 160 attorneys throughout California, Knobbe, Martens, Olson & Bear, LLP represents clients in all areas of intellectual property law and litigation. Clients include public and private companies at various stages of growth, from start-up to the Fortune 500. Founded in 1962, the firm is one of the largest intellectual property law firms in the United States.

More about the firm can be found on its Web site:
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Apr 21, 2004
Previous Article:ASML Announces 2004 First Quarter Results.
Next Article:Concurrent Introduces ImaGen Family of Linux-based Visual Servers.

Related Articles
Consumer class actions follow suits by generic drug makers against brand-name companies.
Brand name companies oppose review of drug industry. (Health).
Quinolone safety and efficacy more important than potency.
Telithromycin for the treatment of acute bacterial maxillary sinusitis: a review of a new antibacterial agent.
Takeda Pharmaceutical Wins Patent Infringement Case on ACTOS in US.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters